07:00 , Apr 16, 2012 |  BC Week In Review  |  Company News

Alfresa Pharma, Sanofi deal

The companies partnered to develop and commercialize epilepsy treatment vigabatrin in Japan to treat children with epilepsia nutans. The irreversible inhibitor of GABA transaminase (GABA T) is marketed as Sabril . Details were not disclosed....
08:00 , Dec 5, 2011 |  BC Week In Review  |  Clinical News

Modiodal modafinil regulatory update

Mitsubishi and Alfresa said Japan approved Modiodal modafinil for excessive diurnal sleepiness accompanied by obstructive sleep apnea (OSA) syndrome in patients under treatment for airway obstruction by continuous positive airway pressure therapy. Mitsubishi and Alfresa...
07:00 , Oct 23, 2008 |  BC Innovations  |  Cover Story

Suppressing the Suppressors

Last week's termination of Cell Genesys Inc. 's Phase III trial of GVAX for prostate cancer is the latest in a long line of failures for cancer vaccine developers. A variety of molecular and cellular...